Carotid artery stenosis

CES 2021 Mission for the human race, Pulxion's early detection technology is here to save lives

Thursday, January 14, 2021 - 8:04am

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the team's research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

CES 2021 Mission for the Human Race, Pulxion’s Early Detection Technology Is Here to Save Lives.

Thursday, January 14, 2021 - 4:58am

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the teams research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

The Cardiovascular Care Group Leading the Way with New Innovative TCAR Procedure to Treat Carotid Artery Disease

Wednesday, October 28, 2020 - 3:00pm

SCOTCH PLAINS, N.J., Oct. 28, 2020 /PRNewswire-PRWeb/ -- The Cardiovascular Care Group, in 2017, was the first group in New Jersey to treat carotid artery disease using a new procedure called TransCarotid Artery Revascularization (TCAR).

Key Points: 
  • SCOTCH PLAINS, N.J., Oct. 28, 2020 /PRNewswire-PRWeb/ -- The Cardiovascular Care Group, in 2017, was the first group in New Jersey to treat carotid artery disease using a new procedure called TransCarotid Artery Revascularization (TCAR).
  • TCAR is a clinically proven, minimally invasive and safe approach for high-risk patients who require carotid artery treatment.
  • Carotid artery disease is a form of atherosclerosis, or a buildup of plaque, in the main arteries in the neck that supply oxygen-rich blood to the brain.
  • Prior to TCAR, the main treatment option for severe carotid artery disease was an open surgical procedure called carotid endarterectomy (CEA).

Silk Road Medical Names Rick Anderson to Board of Directors

Thursday, October 1, 2020 - 9:05pm

SUNNYVALE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that medical device industry veteran Rick Anderson has joined its board of directors.

Key Points: 
  • SUNNYVALE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that medical device industry veteran Rick Anderson has joined its board of directors.
  • He also previously served as Chairman of the Board for Cardiva Medical, IDEV Technologies, and Tryton Medical, and served as Director on the boards of Intersect ENT and multiple other medical device companies.
  • Silk Road Medical has revolutionized the treatment of carotid artery disease and I am honored to be joining the Board of Directors, said Anderson.
  • Silk Road Medical, Inc. (NASDAQ: SILK),is a medical device company located inSunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact.

Compelling Outcomes with TCAR vs. CEA in Patients with Carotid Artery Stenosis Published in the Annals of Surgery

Monday, September 21, 2020 - 2:00pm

These promising outcomes will likely increase the role of TCAR in the management of carotid artery stenosis.

Key Points: 
  • These promising outcomes will likely increase the role of TCAR in the management of carotid artery stenosis.
  • The study evaluated patients who underwent carotid procedures between 2016 and 2019, with 6,384 patients in each group analyzed using propensity score matching.
  • Additionally, there were no statistical differences noted between TCAR and CEA for in-hospital stroke/death (TCAR, 1.6%; CEA, 1.6%, p=0.945) as well as stroke (TCAR, 1.4%; CEA, 1.4%, p=0.881) and death (TCAR, 0.4%; CEA, 0.3%, p=0.662).
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).

ROADSTER 2 Data Publication in Stroke Demonstrates Compelling Patient Outcomes and Strong Safety Profile with TCAR

Wednesday, August 19, 2020 - 9:05pm

The article, Early Outcomes in the ROADSTER 2 Study of TransCarotid Artery Revascularization (TCAR) in Patients with Significant Carotid Artery Disease demonstrates compelling patient outcomes with low stroke and combined stroke and death rates when utilizing TCAR.

Key Points: 
  • The article, Early Outcomes in the ROADSTER 2 Study of TransCarotid Artery Revascularization (TCAR) in Patients with Significant Carotid Artery Disease demonstrates compelling patient outcomes with low stroke and combined stroke and death rates when utilizing TCAR.
  • The publication of the ROADSTER 2 data in Stroke provides further validation of the work we are doing to improve patient safety and deliver strong clinical outcomes.
  • We are honored that ROADSTER 2 was included in this prestigious, widely read, peer reviewed journal as we continue our mission to broaden TCAR adoption.
  • The ROADSTER 2 data show stroke and combined stroke and death rates comparable to CEA in 692 high surgical risk patients enrolled in the FDA analysis population, across 43 sites.

Society for Vascular Surgery (SVS) Issues Guidance on Competence Recommendations for TCAR

Tuesday, June 30, 2020 - 9:05pm

The competence statement, published in the Journal of Vascular Surgery, provides recommendations on physician training and skills required to obtain and maintain clinical privileges to perform TCAR within an institution.

Key Points: 
  • The competence statement, published in the Journal of Vascular Surgery, provides recommendations on physician training and skills required to obtain and maintain clinical privileges to perform TCAR within an institution.
  • The statement outlines three credentialing pathways for physicians, providing multiple options to obtain the requisite endovascular and surgical skills.
  • The physician training recommendations in the statement vary based on prior experience and, importantly, are consistent with the training program offered by Silk Road Medical.
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS PARADIGM Trial in EuroIntervention

Wednesday, June 10, 2020 - 1:00pm

101 unselected consecutive patients for carotid revascularization were enrolled in the PARADIGM trial.

Key Points: 
  • 101 unselected consecutive patients for carotid revascularization were enrolled in the PARADIGM trial.
  • At 30 days, only one adverse event occurred (a minor transient stroke with no other strokes, myocardial infarctions, or deaths.
  • This is substantiated by a new paper in EuroIntervention, a prestigious medical journal covering the latest advancements in vascular intervention.
  • We believe these new data demonstrate the sustained safety of our unique CGuard EPS system incorporating proprietary MicroNet technology.

InspireMD to Report First Quarter 2020 Financial Results and Provide Business Update on Tuesday, May 12

Tuesday, May 5, 2020 - 1:00pm

TEL AVIV, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that management will host a conference call and webcast on Tuesday, May 12, 2020, to discuss financial results for the first quarter ended March 31, 2020, and provide a corporate update.

Key Points: 
  • TEL AVIV, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that management will host a conference call and webcast on Tuesday, May 12, 2020, to discuss financial results for the first quarter ended March 31, 2020, and provide a corporate update.

InspireMD to Report Fourth Quarter 2019 Financial Results and Provide Business Update on Tuesday, March 10

Tuesday, March 3, 2020 - 1:00pm

TEL AVIV, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, March 10, 2020, to discuss financial results for the fourth quarter and year ended December 31, 2019, and provide a corporate update.

Key Points: 
  • TEL AVIV, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, March 10, 2020, to discuss financial results for the fourth quarter and year ended December 31, 2019, and provide a corporate update.